Differentiated IP base
Novelty in Composition
Disease-modifying mechanism via
innovative pharmacokinetic effects and safe with newly created molecular compounds from natural ingredients
Curyx and its portfolio companies have award-winning scientific teams widely recognized in neuroscience field & experienced management team with track record founding biotech companies and financial services background
Who We Are
As one of the portfolio drug development companies under Curyx Partners platform, Liberyx Therapeutics is dedicated to develop innovative drugs for rare pediatric diseases. Not all drug development is the same. Our approach is very unique in that we try to bring technologies that can be quickly commercialized with patient-friendly administration in highly unmet areas of rare indications, such as rare pediatric metabolic disorders.
Furthermore, our business model enables us to, firstly use minimal amount of capital in a highly efficient manner to reach milestones and, secondly create substantive inflection points at early phases which will reflect significant corporate values to commercialize our drug candidates quickly to make them available for our patients.”
Liberyx Therapeutics Completes Series A Fundraising
May 06, 2022, 06:42 GMT
With multiple promising candidates for rare neurometabolic disorders, Liberyx Therapeutics is at the forefront of developing safe and efficacious therapies for our patients.
For Any Queries,
Chat With Us
Unit 805, 8/F Mirror Tower, 61 Mody Road, Tsim Sha Tsui, Kowloon, Hong Kong
140 E. Ridgewood Avenue Suite 415, South Tower Paramus NJ 07652 US